55results about How to "Improve intestinal barrier function" patented technology

The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating visceral pain.

The present invention relates to novel isolated strains of Bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (TER) of a Caco-2 cell monolayer after 10 h treatment to more than 120% of TER at treatment start, ii) inducing secretion of >200 pg/ml of IL-10, and/or iii) inducing an IL-10:IL-12 ratio>1 when co-incubated with human PBMC derived dendritic cells. The strains may have one, two or all three of these capabilities. The present invention relates to the use of these novel strains for the in prevention, alleviation of symptoms, and treatment of diseases or conditions with an underlying impaired intestinal barrier function and pro-inflammatory activation of the mucosa. More specifically, the present invention relates to se of an isolated strain according to the invention for the prevention, alleviation of symptoms, or treatment of intestinal inflammatory conditions such as IBD and IBS, liver diseases such as NAFLD, NASH, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, type 2 diabetes, obesity, cardiovascular atherosclerosis, autoimmune diseases, such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.

The invention relates to novel, probiotic, anti-inflammatory strains of Bifidobacterium longum, their use for treatment of diseases, and for preparation of human or pet food or pharmaceutical compositions. The strains produce high amounts of exopolysaccharides with a high content of mannose- and glucose residues. Accordingly, the invention also relates to a bacterial polysaccharide composition obtained from the strains, their use for treatment of diseases, and pharmaceutical compositions comprising such polysaccharides.

The invention discloses a preservation number of CCTCC NO: M 2019595 Lactobacillus plantarumS58 and application thereof in preparation of products such as health care products, foods and medicines forrelieving obesity. The invention not only expands the application range of the Lactobacillus plantarumS58 and improves the utilization value of the Lactobacillus plantarumS58, but also brings new hope for treating obesity.

The invention discloses a lactic acid bacteria formula for preventing acute and chronic alcoholic liver injury and application thereof. Lactobacillus plantarum KLDS1.0344 and lactobacillus acidophilusKLDS1.0901 have good gastrointestinal fluid tolerance simulating capacity, have certain adhesion capacity to HT-29 cells and have basic probiotic characteristics; the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent acute alcoholic liver injury; and the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent chronic alcoholic liver injury. Specifically, the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 have the functions of reducing the liver index, improving the intestinal barrier, improving the liver function, reducing the inflammation level in the liver, increasing the content of short-chain fatty acid in the intestinal tract, reducing protein expression of CYP2E1 in the liver and the like.

The invention relates to a liquid nutrition comprising short chain fatty acyl chains, polyunsaturated fatty acyl chains, vegetable oil and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.

The invention discloses application of lysozyme or a combination comprising the lysozyme to preparation of a medicine for preventing or treating COVID-19 and application to preparation of food for assisting in preventing or treatment COVID-19. The lysozyme or the combination thereof provided by the invention can effectively inhibit cell damage caused by novel coronavirus virus, inhibit inflammatory factor expression induced by novel coronavirus virus, improve airway obstruction and expiratory volume reduction caused by pulmonary lesions, and improve intestinal barrier dysfunction. The composition has a good effect on high virus load, respiratory distress, intestinal function impairment and the like of patients, and can reduce the infection rate of novel coronavirus virus and reduce the novel coronavirus rate of pneumonia severe case. In addition, because the lysozyme is extremely high in safety, the lysozyme also has a very important value for preventing novel coronavirus disease of undiagnosed novel coronavirus virus high-risk infected people.

A nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by S. thermophilus. Said combination reduces bacterial translocation and improves the intestinal barrier function.

This invention relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.

The invention relates to the technical field of pig feed preparation and particularly discloses a formula feed for improving an intestinal barrier function of an early weaned piglet and a feeding method of the formula feed. The formula feed comprises basal diet and a feed additive; the feed additive comprises MOS occupying 0.10-0.20 percent of the mass percentage of the basal diet and Ala-Gln occupying 0.15-0.30 percent of the mass percentage of the basal diet. When the formula feed disclosed by the invention is used for feeding the early weaned piglet, the average daily feed intake of the weaned stress piglet can be significantly improved, so that the feed-weight ratio of the weaned stress piglet is significantly reduced, the villus height/crypt depth of each of duodenum and ileum is significantly improved, the jejunum crypt depth is significantly reduced, and the diarrhea rate of the weaned stress piglet is significantly reduced; after the weaned piglet is fed for 28 days, an interaction effect on the villus height of the duodenum and the villus height/crypt depth is realized. The formula feed disclosed by the invention is easy for raw material obtaining, simple in preparation method and convenient to use.

The invention discloses an application of atractylodes macrocephala polysaccharide and pachymaran as a feed additive for improving intestinal health of piglets, which belongs to the field of the feedadditive. The application of atractylodes macrocephala polysaccharide and pachymaran as feed additive for improving intestinal health of piglets is characterized in that the appropriate addition amount accounts for 0.02%-0.08% of mass of a basic feed, the overhigh addition amount affect the growth performance, immunity and feed-to-weight ratio of the piglets, and the excessive low addition amountcannot achieve the effect; the atractylodes macrocephala polysaccharide and pachymaran is composed of atractylodes macrocephala polysaccharide and pachymaran according to a mass ratio of 1-2:1-2, thecontent of polysaccharides in atractylodes macrocephala polysaccharide and pachymaran is 37.5%; and the application of atractylodes macrocephala polysaccharide and pachymaran as the feed additive forimproving intestinal health of the piglets can effectively improve the intestinal barrier function of the early weaned piglets, improves the intestinal health of piglets, and can replace the antibiotics in promoting the growth performance of the piglets.

Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.

Provided are an intestinal barrier function enhancer capable of enhancing intestinal barrier function and thereby capable of preventing or treating metabolic syndrome, and a drug and a food or drink containing the same. An intestinal barrier function enhancer containing cells or a treated cell product of Lactobacillus crustorum. This intestinal barrier function enhancer functions effectively to enhance intestinal barrier function and to prevent or treat conditions or diseases caused by impaired intestinal barrier function such as metabolic syndrome and the like.

The invention relates to bacillus cereus, the scientific name of the bacillus cereus is Bacillus cereus HMPM18123, the preservation date is July 30, 2021, the preservation unit is Guangdong Microbial Culture Collection Center, the preservation place is the 5th floor, No.59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation code is GDMCC61838. The invention discloses application of bacillus cereus in preparation of functional microbial agents, food and/or medicines for improving ulcerative colitis, reducing pathological injury of enteritis intestinal tissues, inhibiting inflammation, improving the barrier function of intestinal tracts and improving intestinal flora composition. The traditional Chinese medicine composition has the advantages of high practical application value and small toxic and side effects, and has a very obvious effect on treating ulcerative colitis.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.